| Year |
Citation |
Score |
| 2024 |
Bose M, Sanders A, Handa A, Vora A, Cardona MR, Brouwer C, Mukherjee P. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers. Scientific Reports. 14: 3178. PMID 38326371 DOI: 10.1038/s41598-024-53549-4 |
0.436 |
|
| 2024 |
Zhou R, Wu ST, Yazdanifar M, Williams C, Sanders A, Brouwer C, Maher J, Mukherjee P. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 38270462 DOI: 10.1097/CJI.0000000000000505 |
0.416 |
|
| 2022 |
Bose M, Sanders A, De C, Zhou R, Lala P, Shwartz S, Mitra B, Brouwer C, Mukherjee P. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Translational Research : the Journal of Laboratory and Clinical Medicine. PMID 36031050 DOI: 10.1016/j.trsl.2022.08.010 |
0.512 |
|
| 2022 |
Tarannum M, Holtzman K, Dréau D, Mukherjee P, Vivero-Escoto JL. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 347: 425-434. PMID 35569588 DOI: 10.1016/j.jconrel.2022.05.019 |
0.377 |
|
| 2022 |
Bose M, Grover P, Sanders AJ, Zhou R, Ahmad M, Shwartz S, Lala P, Nath S, Yazdanifar M, Brouwer C, Mukherjee P. Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. Frontiers in Cell and Developmental Biology. 10: 821875. PMID 35237602 DOI: 10.3389/fcell.2022.821875 |
0.778 |
|
| 2021 |
Sahraei M, Bose M, Sanders JA, De C, DasRoy L, Nath S, Brouwer CR, Mukherjee P. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models. International Journal of Molecular Sciences. 22. PMID 34070449 DOI: 10.3390/ijms22115587 |
0.796 |
|
| 2020 |
Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, Mukherjee P. Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Frontiers in Immunology. 11: 628776. PMID 33365036 DOI: 10.3389/fimmu.2020.628776 |
0.368 |
|
| 2020 |
Kelly VJ, Wu ST, Gottumukkala V, Coelho R, Palmer K, Nair S, Erick T, Puri R, Ilovich O, Mukherjee P. Preclinical evaluation of an In/Ac theranostic targeting transformed MUC1 for triple negative breast cancer. Theranostics. 10: 6946-6958. PMID 32550914 DOI: 10.7150/Thno.38236 |
0.5 |
|
| 2019 |
Bose M, Mukherjee P. Microbe-MUC1 Crosstalk in Cancer-Associated Infections. Trends in Molecular Medicine. PMID 31753595 DOI: 10.1016/J.Molmed.2019.10.003 |
0.405 |
|
| 2019 |
Curry JM, Besmer DM, Erick TK, Steuerwald N, Das Roy L, Grover P, Rao S, Nath S, Ferrier JW, Reid RW, Mukherjee P. Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice. Plos One. 14: e0224309. PMID 31693710 DOI: 10.1371/Journal.Pone.0224309 |
0.815 |
|
| 2019 |
Erick TK, Mukherjee P. Modulating MUC1 Function on T Cells. Trends in Immunology. PMID 31653412 DOI: 10.1016/J.It.2019.09.007 |
0.417 |
|
| 2019 |
Bose M, Mukherjee P. Role of Microbiome in Modulating Immune Responses in Cancer. Mediators of Inflammation. 2019: 4107917. PMID 31308831 DOI: 10.1155/2019/4107917 |
0.412 |
|
| 2019 |
Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, Mukherjee P. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Frontiers in Immunology. 10: 1149. PMID 31178870 DOI: 10.3389/Fimmu.2019.01149 |
0.5 |
|
| 2019 |
Dréau D, Moore LJ, Wu M, Roy LD, Dillion L, Porter T, Puri R, Momin N, Wittrup KD, Mukherjee P. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology. 9: 330. PMID 31114758 DOI: 10.3389/Fonc.2019.00330 |
0.492 |
|
| 2019 |
Yazdanifar M, Zhou R, Wu S, Grover P, Mukherjee P. Abstract 584: Developing a novel engineered T cell to target resistant pancreatic cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-584 |
0.401 |
|
| 2019 |
Zhou R, Yazdanifar M, Roy LD, Maher J, Mukherjee P. Abstract 2305: Tumor MUC1 glycoprotein-highly specific CAR T cells control triple-negative breast cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-2305 |
0.488 |
|
| 2019 |
ilovich o, Kelly V, Wu S, Gottumukkala V, Coelho R, Puri R, Mukherjee P. Abstract LB-281: Development and non-clinical evaluation of an111In/225Ac theranostic for triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-281 |
0.494 |
|
| 2019 |
Grover P, Zhou R, Yazdanifar M, Ahmad M, Puri A, Grover K, Shi X, Mukherjee P. Abstract 2636: Tumor associated MUC1 mediates TGF-β in pancreatic cancer Cancer Research. 79: 2636-2636. DOI: 10.1158/1538-7445.Am2019-2636 |
0.507 |
|
| 2019 |
Bose M, Mukherjee P. Abstract 2052: A novel antibody blocks anti-apoptotic activity of MUC1 in pancreatic cancer cell lines Cancer Research. 79: 2052-2052. DOI: 10.1158/1538-7445.Am2019-2052 |
0.535 |
|
| 2019 |
Ilovich O, Kelly V, Wu S, Vijay G, Coelho R, Rahul P, Mukherjee P. Development and Non-clinical Evaluation of an 111In/225Ac Theranostic for Triple Negative Breast Cancer Journal of Medical Imaging and Radiation Sciences. 50: S40-S41. DOI: 10.1016/J.Jmir.2019.03.123 |
0.363 |
|
| 2018 |
Wu ST, Fowler AJ, Garmon CB, Fessler AB, Ogle JD, Grover KR, Allen BC, Williams CD, Zhou R, Yazdanifar M, Ogle CA, Mukherjee P. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. Bmc Cancer. 18: 457. PMID 29685122 DOI: 10.1186/S12885-018-4393-7 |
0.405 |
|
| 2018 |
Nazari SS, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer (Tokyo, Japan). PMID 29651637 DOI: 10.1007/S12282-018-0857-5 |
0.373 |
|
| 2018 |
Grover P, Nath S, Nye MD, Zhou R, Ahmad M, Mukherjee P. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line. Oncotarget. 9: 6897-6910. PMID 29467938 DOI: 10.18632/Oncotarget.23966 |
0.769 |
|
| 2018 |
Wu ST, Williams CD, Grover PA, Moore LJ, Mukherjee P. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004. Plos One. 13: e0193260. PMID 29462213 DOI: 10.1371/Journal.Pone.0193260 |
0.412 |
|
| 2018 |
Wu S, Gottumukkala V, Coelho R, Moore LJ, Kelly V, Ilovich O, Puri R, Mukherjee P. Development of targeted radiotherapy for triple negative breast cancer. Journal of Clinical Oncology. 36: e13112-e13112. DOI: 10.1200/Jco.2018.36.15_Suppl.E13112 |
0.474 |
|
| 2018 |
Nazari S, Mukherjee P. Abstract 184: Three-dimensional density model promotes invasive characteristics in normal mammary epithelial cells Tumor Biology. DOI: 10.1158/1538-7445.Am2018-184 |
0.361 |
|
| 2017 |
Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P. A tumor specific antibody to aid breast cancer screening in women with dense breast tissue. Genes & Cancer. 8: 536-549. PMID 28680538 DOI: 10.18632/Genesandcancer.134 |
0.327 |
|
| 2017 |
Salmon JS, Hwang JJ, Robinson MM, Symanowski JT, Dillon LM, Das Roy L, Beldner MA, Preston K, Buige S, Nazemzadeh R, Mukherjee P, Farhangfar F, Kim ES. Phase II study of regorafenib (Reg) in patients with previously treated advanced pancreatic cancer (APC). Journal of Clinical Oncology. 35: e15751-e15751. DOI: 10.1200/Jco.2017.35.15_Suppl.E15751 |
0.33 |
|
| 2017 |
Mukherjee P, Zhou R, Yazdanifar M, Lopamudra DR. Abstract A37: Development and future of CAR T cell therapy for pancreatic ductal adenocarcinoma and triple negative breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Newfront17-A37 |
0.547 |
|
| 2017 |
Yazdanifar M, Zhou R, Wu S, Grover P, Mukherjee P. Abstract 4708: A novel anti-MUC1 CAR T cell drives immunity to pancreatic cancer Cancer Research. 77: 4708-4708. DOI: 10.1158/1538-7445.Am2017-4708 |
0.486 |
|
| 2017 |
Nazari S, Mukherjee P. Abstract 4326: Tissue density can create a carcinogenic microenvironment for normal mammary epithelial cells Cancer Research. 77: 4326-4326. DOI: 10.1158/1538-7445.Am2017-4326 |
0.334 |
|
| 2017 |
Grover P, Nye MD, Yazdanifar M, Ahmad M, Zhou R, Roy LD, Grover K, Wu S, Nath S, Mukherjee P. Abstract 321: MUC1 regulates TGFβ function in pancreatic cancer Cancer Research. 77: 321-321. DOI: 10.1158/1538-7445.Am2017-321 |
0.77 |
|
| 2017 |
Vivero-Escoto JL, Jeffords LM, Dréau D, Alvarez-Berrios M, Mukherjee P. Mucin1 antibody-conjugated dye-doped mesoporous silica nanoparticles for breast cancer detection in vivo Proceedings of Spie. 10078. DOI: 10.1117/12.2252369 |
0.458 |
|
| 2016 |
Yazdanifar M, Zhou R, Mukherjee P. Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. Current Trends in Immunology. 17: 95-115. PMID 28659689 |
0.353 |
|
| 2016 |
Dréau D, Moore LJ, Alvarez-Berrios MP, Tarannum M, Mukherjee P, Vivero-Escoto JL. Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast Cancer Detection in a Mucin-1 Transgenic Murine Mouse Model. Journal of Biomedical Nanotechnology. 12: 2172-2184. PMID 28522938 DOI: 10.1166/Jbn.2016.2318 |
0.443 |
|
| 2016 |
Zhou R, Curry JM, Roy LD, Grover P, Haider J, Moore LJ, Wu ST, Kamesh A, Yazdanifar M, Ahrens WA, Leung T, Mukherjee P. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Oncogene. PMID 26804176 DOI: 10.1038/Onc.2015.516 |
0.424 |
|
| 2016 |
Roy LD, Zhou R, Dillon L, Moore L, Puri R, Marks J, Lyerly H, Mukherjee P. Abstract P4-09-16: A monoclonal antibody with exceptional specificity across major breast cancer subtypes Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-09-16 |
0.481 |
|
| 2016 |
Wu S, Fowler AJ, Ogle C, Mukherjee P. Abstract 1323: Targeting tMUC1 for the diagnostics and treatment of pancreatic cancer Cancer Research. 76: 1323-1323. DOI: 10.1158/1538-7445.Am2016-1323 |
0.462 |
|
| 2015 |
Moore LJ, Das Roy L, Wu ST, Puri R, Mukherjee P. Early detection of mammary tumors in vivo using a highly specific tumor antibody. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 14. PMID 28147824 DOI: 10.1200/Jco.2015.33.28_Suppl.14 |
0.474 |
|
| 2015 |
Nath S, Roy LD, Grover P, Rao S, Mukherjee P. Mucin 1 Regulates Cox-2 gene in Pancreatic Cancer. Pancreas. PMID 26035123 DOI: 10.1097/Mpa.0000000000000371 |
0.787 |
|
| 2015 |
Das Roy L, Zhou R, Moore LJ, Dillon LM, Puri R, Lyerly K, Marks JR, Mukherjee P. Early detection of breast cancer using a unique tumor specific antibody. Journal of Clinical Oncology. 33: e22153-e22153. DOI: 10.1200/Jco.2015.33.15_Suppl.E22153 |
0.424 |
|
| 2015 |
Grover P, Nath S, Ahmad M, Mukherjee P. Abstract 2054: In pancreatic cancer, MUC1 regulates function of TGF-β and thus enhances metastasis Cancer Research. 75: 2054-2054. DOI: 10.1158/1538-7445.Am2015-2054 |
0.788 |
|
| 2014 |
Nath S, Bhowmick S, Dutta T, Chowrasia VR, Bhattacharya S, Chatterjee RN, Sarkar M, Ram AK, Mukherjee PK. A study of promotional advertisements of drugs in a medical journal: an ethics perspective. Indian Journal of Medical Ethics. 11: 237-41. PMID 25377037 DOI: 10.20529/IJME.2014.059 |
0.672 |
|
| 2014 |
Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. Bmc Cancer. 14: 225. PMID 24674692 DOI: 10.1186/1471-2407-14-225 |
0.75 |
|
| 2014 |
Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine. 20: 332-42. PMID 24667139 DOI: 10.1016/J.Molmed.2014.02.007 |
0.798 |
|
| 2014 |
Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 63: 513-28. PMID 24652403 DOI: 10.1007/S00262-014-1527-X |
0.436 |
|
| 2014 |
Kidiyoor A, Schettini J, Besmer DM, Rego SL, Nath S, Curry JM, Roy LD, Dréau D, Mukherjee P. Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. Frontiers in Immunology. 5: 67. PMID 24605110 DOI: 10.3389/Fimmu.2014.00067 |
0.823 |
|
| 2014 |
Wu S, Fowler A, Ogle C, Mukherjee P. Abstract 4484: Anti-cancer treatments delivered by antibody guided PLGA nanoparticles Cancer Research. 74: 4484-4484. DOI: 10.1158/1538-7445.Am2014-4484 |
0.392 |
|
| 2014 |
Zhou R, Curry J, Grover P, Roy LD, Leung T, Mukherjee P. Abstract 26: MUC1 enhances neuropilin-1 signaling in pancreatic ductal adenocarcinoma Cancer Research. 74: 26-26. DOI: 10.1158/1538-7445.Am2014-26 |
0.567 |
|
| 2013 |
Hastie E, Besmer DM, Shah NR, Murphy AM, Moerdyk-Schauwecker M, Molestina C, Roy LD, Curry JM, Mukherjee P, Grdzelishvili VZ. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. Journal of Virology. 87: 10283-94. PMID 23864625 DOI: 10.1128/Jvi.01412-13 |
0.792 |
|
| 2013 |
Rego SL, Swamydas M, Kidiyoor A, Helms R, De Piante A, Lance AL, Mukherjee P, Dréau D. Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 33: 672-81. PMID 23777205 DOI: 10.1089/Jir.2013.0009 |
0.426 |
|
| 2013 |
Nath S, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, Sahraei M, Mukherjee P. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2: e51. PMID 23774063 DOI: 10.1038/oncsis.2013.16 |
0.76 |
|
| 2013 |
Das Roy L, Curry JM, Sahraei M, Besmer DM, Kidiyoor A, Gruber HE, Mukherjee P. Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Research : Bcr. 15: R32. PMID 23577751 DOI: 10.1186/Bcr3412 |
0.802 |
|
| 2013 |
Curry JM, Thompson KJ, Rao SG, Besmer DM, Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D, Iannitti DA, Martinie JB, Mukherjee P. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. Journal of Surgical Oncology. 107: 713-22. PMID 23335066 DOI: 10.1002/Jso.23316 |
0.809 |
|
| 2013 |
Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology. 436: 221-34. PMID 23246628 DOI: 10.1016/J.Virol.2012.11.014 |
0.417 |
|
| 2013 |
Curry JM, Besmer DM, Roy LD, Grover P, Nath S, Rao S, Mukherjee P. Abstract 475: Combinational treatment with MUC1 vaccine and Indomethacin reduces breast tumor burden via a COX-independent pathway. Cancer Research. 73: 475-475. DOI: 10.1158/1538-7445.Am2013-475 |
0.794 |
|
| 2013 |
Nath S, Roy LD, Rao S, Grover P, Mukherjee P. Abstract 3119: MUC1 transcriptionally regulates COX-2 gene in pancreatic cancer cells. Cancer Research. 73: 3119-3119. DOI: 10.1158/1538-7445.Am2013-3119 |
0.82 |
|
| 2013 |
Rego S, Helms R, Piante AD, Kidiyoor A, Lance A, Mukherjee P, Dréau D. Abstract 1540: TNFRs shed by tumor cells inhibit the migration of macrophages. Cancer Research. 73: 1540-1540. DOI: 10.1158/1538-7445.Am2013-1540 |
0.501 |
|
| 2012 |
Chauhan VS, Nelson DA, Roy LD, Mukherjee P, Bost KL. Exacerbated metastatic disease in a mouse mammary tumor model following latent gammaherpesvirus infection. Infectious Agents and Cancer. 7: 11. PMID 22642913 DOI: 10.1186/1750-9378-7-11 |
0.396 |
|
| 2012 |
Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunology, Immunotherapy : Cii. 61: 2055-65. PMID 22543528 DOI: 10.1007/S00262-012-1264-Y |
0.803 |
|
| 2012 |
Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, Kidiyoor A, Dalia R, Gendler SJ, Mukherjee P. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene. 31: 4935-45. PMID 22266848 DOI: 10.1038/Onc.2011.651 |
0.83 |
|
| 2012 |
Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, Grdzelishvili VZ. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. Journal of Virology. 86: 3073-87. PMID 22238308 DOI: 10.1128/Jvi.05640-11 |
0.775 |
|
| 2012 |
Nath S, Daneshvar K, Puri N, Mukherjee P. Abstract LB-348: Chemoresistance in pancreatic cancer is conferred by MUC1 cytoplasmic tail binding to the promoter region of the ABCC1 (MRP-1) gene Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-348 |
0.79 |
|
| 2012 |
Besmer D, Kidiyoor A, Nath S, Roy LD, Curry J, Mukherjee P. Abstract 5400: Investigating the role of IDO in MUC1 expressing breast cancers Cancer Research. 72: 5400-5400. DOI: 10.1158/1538-7445.Am2012-5400 |
0.838 |
|
| 2012 |
Murphy A, Besmer D, Moerdyk-Schauwecker M, Moestl N, Ornelles D, Mukherjee P, Grdzelishvili V. Abstract 2714: Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma Cancer Research. 72: 2714-2714. DOI: 10.1158/1538-7445.Am2012-2714 |
0.816 |
|
| 2012 |
Roy LD, Curry JM, Sahraei M, Kidiyoor A, Besmer DM, Gruber HE, Mukherjee P. Abstract 1389: Arthritis augments breast cancer metastasis: Role of mast cells and SCF/c-Kit signaling Cancer Research. 72: 1389-1389. DOI: 10.1158/1538-7445.Am2012-1389 |
0.827 |
|
| 2011 |
Roy LD, Ghosh S, Pathangey LB, Tinder TL, Gruber HE, Mukherjee P. Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. Bmc Cancer. 11: 365. PMID 21859454 DOI: 10.1186/1471-2407-11-365 |
0.321 |
|
| 2011 |
Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, Hwang SI, Lee YY, Gendler SJ, Mukherjee P. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Research. 71: 4432-42. PMID 21558393 DOI: 10.1158/0008-5472.Can-10-4439 |
0.836 |
|
| 2011 |
Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, Gendler SJ, Mukherjee P. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 30: 1449-59. PMID 21102519 DOI: 10.1038/Onc.2010.526 |
0.814 |
|
| 2011 |
Kidiyoor A, Schettini J, Roy LD, Besmer D, Tinder T, Mukherjee P. Abstract 3644: Pancreatic tumor cells that develop within Muc1 knock-out mice generate less immunosuppressive MDSCs in vitro Cancer Research. 71: 3644-3644. DOI: 10.1158/1538-7445.Am2011-3644 |
0.835 |
|
| 2011 |
Nath S, Rao S, Tinder TL, Gendler S, Mukherjee P. Abstract 2910: Oncogenic role of MUC1 in context of TGF-β production and signaling Cancer Research. 71: 2910-2910. DOI: 10.1158/1538-7445.Am2011-2910 |
0.785 |
|
| 2011 |
Curry JM, Thompson KJ, Rao S, Ahrens WA, McKillop IH, Sindram D, Iannitti DA, Martinie JB, Mukherjee P. Abstract 2454: Pancreatic cancer stem cells (CSCs) express MUC1 and MUC1-expressing pancreatic cancers encompass higher levels of CSCs Cancer Research. 71: 2454-2454. DOI: 10.1158/1538-7445.Am2011-2454 |
0.568 |
|
| 2011 |
Ghosh S, Steuerwald N, Parsons J, Bonkovsky HL, Mukherjee P. Abstract 1573: Early angiogenic switch-associated markers in pancreatic cancer development and progression Cancer Research. 71: 1573-1573. DOI: 10.1158/1538-7445.Am2011-1573 |
0.411 |
|
| 2011 |
Besmer D, Roy LD, Curry J, Tinder T, Manouchehrabadi M, Schettini J, Hwang S, Lee Y, Gendler S, Mukherjee P. Abstract 1070: Pancreatic Ductal Adenocarcinoma (PDA) mice lacking Mucin 1 has a profound defect in tumor growth and metastasis Cancer Research. 71: 1070-1070. DOI: 10.1158/1538-7445.Am2011-1070 |
0.843 |
|
| 2010 |
Pinkhasov J, Alvarez ML, Pathangey LB, Tinder TL, Mason HS, Walmsley AM, Gendler SJ, Mukherjee P. Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model. Cancer Immunology, Immunotherapy : Cii. 59: 1801-11. PMID 20824430 DOI: 10.1007/S00262-010-0906-1 |
0.415 |
|
| 2010 |
Block MS, Markovic S, Northfelt DW, Mukherjee P, Pockaj BA, Nevala WK, Ingle JN, Perez EA, Suman V, Gendler SJ. MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. Journal of Clinical Oncology. 28: TPS113-TPS113. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps113 |
0.332 |
|
| 2010 |
Roy LD, Schettini JL, Gruber HE, Sahraei MM, Mukherjee P. Abstract 4765: Treatment with anti - IL 17 A coupled with COX-2 inhibitor significantly decreases breast cancer associated secondary metastasis in a model of autoimmune arthritis Cancer Research. 70: 4765-4765. DOI: 10.1158/1538-7445.Am10-4765 |
0.458 |
|
| 2010 |
Lakshminarayanan V, Bradley JM, Pathangey LB, Mukherjee P, Suman VJ, Madsen CS, Gendler SJ. Abstract 2403: Glycosylated (Tn) and Anchor-Modified MUC1 Peptide Vaccines Induce Effective Anti tumor Immunity and Break Tolerance in MUC1 Transgenic Mice Cancer Research. 70: 2403-2403. DOI: 10.1158/1538-7445.Am10-2403 |
0.428 |
|
| 2009 |
Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P. Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Research : Bcr. 11: R56. PMID 19643025 DOI: 10.1186/Bcr2345 |
0.421 |
|
| 2009 |
Poh TW, Bradley JM, Mukherjee P, Gendler SJ. Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow. Cancer Research. 69: 3554-62. PMID 19351842 DOI: 10.1158/0008-5472.Can-08-3806 |
0.515 |
|
| 2009 |
Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, Skaar T, De Petris G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. Journal of Immunology (Baltimore, Md. : 1950). 182: 216-24. PMID 19109152 DOI: 10.4049/Jimmunol.182.1.216 |
0.526 |
|
| 2009 |
Gendler S, Pathangey L, Lakshminarayanan V, Mukherjee P, Pockaj B, Suman V, Loserth L, Markovic S, Ingle J. Examination of Immune Competence in Breast Cancer Patients at Six Months Post Surgery and Adjuvant Therapy through Assessment of T Cell and Dendritic Cell Functionality. Cancer Research. 69: 4131-4131. DOI: 10.1158/0008-5472.Sabcs-09-4131 |
0.425 |
|
| 2008 |
Schettini J, Mukherjee P. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Clinical & Developmental Immunology. 2008: 106321. PMID 19190769 DOI: 10.1155/2008/106321 |
0.441 |
|
| 2008 |
Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A, Skaar T, Mukherjee P. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. Journal of Immunology (Baltimore, Md. : 1950). 181: 3116-25. PMID 18713982 DOI: 10.4049/Jimmunol.181.5.3116 |
0.567 |
|
| 2008 |
Roy LD, Pathangey L, Tinder T, Mukherjee P. Breast Cancer Associated Metastasis is Significantly Increased in a Model of Autoimmune Arthritis Nature Precedings. DOI: 10.1038/Npre.2008.2632.1 |
0.405 |
|
| 2007 |
Akporiaye ET, Bradley-Dunlop D, Gendler SJ, Mukherjee P, Madsen CS, Hahn T, Besselsen DG, Dial SM, Cui H, Trevor K. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine. 25: 6965-74. PMID 17707958 DOI: 10.1016/J.Vaccine.2007.06.063 |
0.367 |
|
| 2007 |
Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine. 25: 1607-18. PMID 17166639 DOI: 10.1016/J.Vaccine.2006.11.007 |
0.488 |
|
| 2006 |
Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA, Mukherjee P. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Research : Bcr. 8: R69. PMID 17156488 DOI: 10.1186/Bcr1626 |
0.479 |
|
| 2006 |
Sevcik MA, Jonas BM, Lindsay TH, Halvorson KG, Ghilardi JR, Kuskowski MA, Mukherjee P, Maggio JE, Mantyh PW. Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. Gastroenterology. 131: 900-10. PMID 16952558 DOI: 10.1053/J.Gastro.2006.06.021 |
0.332 |
|
| 2006 |
Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, Mukherjee P. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. Journal of Immunology (Baltimore, Md. : 1950). 177: 2391-402. PMID 16888001 DOI: 10.4049/Jimmunol.177.4.2391 |
0.542 |
|
| 2006 |
Thompson EJ, Shanmugam K, Hattrup CL, Kotlarczyk KL, Gutierrez A, Bradley JM, Mukherjee P, Gendler SJ. Tyrosines in the MUC1 cytoplasmic tail modulate transcription via the extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB pathways. Molecular Cancer Research : McR. 4: 489-97. PMID 16849524 DOI: 10.1158/1541-7786.Mcr-06-0038 |
0.359 |
|
| 2005 |
Lindsay TH, Jonas BM, Sevcik MA, Kubota K, Halvorson KG, Ghilardi JR, Kuskowski MA, Stelow EB, Mukherjee P, Gendler SJ, Wong GY, Mantyh PW. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain. 119: 233-46. PMID 16298491 DOI: 10.1016/J.Pain.2005.10.019 |
0.429 |
|
| 2005 |
Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Research : Bcr. 7: R422-35. PMID 15987447 DOI: 10.1186/Bcr1019 |
0.475 |
|
| 2005 |
Mukherjee P, Tinder TL, Basu GD, Gendler SJ. MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells Journal of Leukocyte Biology. 77: 90-99. PMID 15513966 DOI: 10.1189/Jlb.0604333 |
0.407 |
|
| 2004 |
Mukherjee P, Tinder TL, Basu GD, Pathangey LB, Chen L, Gendler SJ. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. Breast Disease. 20: 53-63. PMID 15687707 DOI: 10.3233/Bd-2004-20107 |
0.535 |
|
| 2004 |
Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Molecular Cancer Research : McR. 2: 632-42. PMID 15561779 |
0.424 |
|
| 2004 |
Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Annals of Surgical Oncology. 11: 328-39. PMID 14993030 DOI: 10.1245/Aso.2004.05.027 |
0.427 |
|
| 2004 |
Basu GD, Pathangey L, Tinder T, LaGioia M, Gendler SJ, Mukherjee P. Role of COX-2 Inhibition in the Treatment of Metastatic Breast Cancer Journal of Immunotherapy. 27: S45. DOI: 10.1097/00002371-200411000-00162 |
0.397 |
|
| 2004 |
Mukherjee P, Tinder T, Basu GD, Pathangey L, Chen L, Gendler SJ. Therapeutic Efficacy of Muci-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model Journal of Immunotherapy. 27: S4. DOI: 10.1097/00002371-200411000-00020 |
0.348 |
|
| 2003 |
Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology. 109: 300-7. PMID 12757626 DOI: 10.1046/J.1365-2567.2003.01656.X |
0.423 |
|
| 2003 |
Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. Journal of Immunology (Baltimore, Md. : 1950). 170: 1980-6. PMID 12574367 DOI: 10.4049/Jimmunol.170.4.1980 |
0.515 |
|
| 2003 |
Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 47-62. PMID 12514429 DOI: 10.1097/00002371-200301000-00006 |
0.562 |
|
| 2002 |
McConnell EJ, Pathangey LB, Madsen CS, Gendler SJ, Mukherjee P. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. The Journal of Surgical Research. 107: 196-202. PMID 12429175 DOI: 10.1006/Jsre.2001.6497 |
0.525 |
|
| 2002 |
Gendler SJ, Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends in Molecular Medicine. 7: 471-5. PMID 11597523 DOI: 10.1016/S1471-4914(01)02124-4 |
0.447 |
|
| 2001 |
Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconjugate Journal. 18: 931-42. PMID 12820727 DOI: 10.1023/A:1022260711583 |
0.539 |
|
| 2000 |
Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, Gendler SJ. Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred Journal of Immunology. 165: 3451-3460. PMID 10975866 DOI: 10.4049/Jimmunol.165.6.3451 |
0.561 |
|
| 1998 |
Ponnazhagan S, Weigel KA, Raikwar SP, Mukherjee P, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: Erythroid cell-specific delivery and expression of transduced genes Journal of Virology. 72: 5224-5230. PMID 9573295 DOI: 10.1128/Jvi.72.6.5224-5230.1998 |
0.352 |
|
| Show low-probability matches. |